A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008 (Q80113399)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16909426%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

title

A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16909426%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16909426%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

8

Eric J Small

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16909426%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

author name string

Walter M Stadler

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16909426%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Brian Rini

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16909426%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Marc S Ernstoff

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16909426%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Enrique Davila

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16909426%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Joel Picus

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16909426%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Robert Barrier

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16909426%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Cancer and Leukemia Group B

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16909426%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

publication date

1 September 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16909426%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16909426%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

volume

107

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16909426%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16909426%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

page(s)

1273-1279

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16909426%20AND%20SRC:MED&resulttype=core&format=json

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

28 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22117

7 January 2021

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22117

7 January 2021

Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22117

7 January 2021

Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22117

7 January 2021

A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22117

7 January 2021

A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22117

7 January 2021

A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22117

7 January 2021

Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22117

7 January 2021

Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22117

7 January 2021

A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22117

7 January 2021

Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22117

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22117

7 January 2021

One-sample multiple testing procedure for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22117

7 January 2021

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22117

7 January 2021

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22117

7 January 2021

Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22117

7 January 2021

Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22117

7 January 2021

Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22117

7 January 2021

Immunotherapy for advanced renal cell cancer.

1 reference

12 January 2024

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD001425

Identifiers

DOI

10.1002/CNCR.22117

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16909426%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference